What are the two forms of semaglutide, and which is approved for weight loss?
Semaglutide is available in two delivery formats with separate FDA-approved indications:
- Oral semaglutide (Rybelsus): Available in 3 mg, 7 mg, and 14 mg tablets. FDA-approved for type 2 diabetes management. Not approved for weight management as a standalone indication.
- Injectable semaglutide (Ozempic, Wegovy): Weekly subcutaneous injection. Ozempic is approved for type 2 diabetes management. Wegovy (2.4 mg weekly) is specifically approved for chronic weight management in adults with obesity or overweight with a weight-related condition.
This distinction matters when you are specifically seeking semaglutide for weight management: the FDA-approved path for that purpose is the injectable form, not the oral tablet. Compounded semaglutide — the form most commonly prescribed through telehealth platforms — is most often injectable as well, though clinician-prescribed oral compounded forms exist.
Oral vs. injectable semaglutide: how do they compare for weight loss?
| Factor | Oral semaglutide (Rybelsus) | Injectable semaglutide |
|---|---|---|
| FDA weight-loss indication | No (diabetes only) | Yes — Wegovy 2.4 mg/week |
| Approved doses | 3 mg, 7 mg, 14 mg (daily) | 0.25–2.4 mg (weekly) |
| Bioavailability | ~1% (requires fasting + SNAC) | ~89% subcutaneous |
| Dosing adherence burden | Daily; strict 30-min empty-stomach window | Once weekly; no fasting required |
| Compounded form available | No — SNAC technology is proprietary | Yes — via licensed 503A pharmacies |
| Weight outcomes (PIONEER vs. STEP trials) | ~3–5 kg over 26–52 weeks (diabetes context) | ~15% body weight over 68 weeks (STEP 1) |
Data sourced from PIONEER 6 (NEJM 2019) and STEP 1 (NEJM 2021) trials. Individual results vary. Compounded semaglutide is not FDA-approved; it is prepared by licensed 503A pharmacies under a clinician’s prescription.
Why does oral semaglutide have lower bioavailability?
Peptides like semaglutide face a fundamental challenge with oral delivery: they are composed of amino acids and are subject to degradation by proteolytic enzymes in the GI tract. Additionally, the GI mucosal barrier limits absorption of large polar molecules like peptides.
Novo Nordisk addressed this for Rybelsus by co-formulating semaglutide with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), a proprietary absorption enhancer that creates a local alkaline microenvironment in the stomach and transiently increases mucosal permeability to allow semaglutide absorption.
Even with this technology, the bioavailability of oral semaglutide is approximately 1% under optimal conditions — substantially below the bioavailability of the subcutaneous injectable form. To compensate, the oral doses are milligram-range (3–14 mg daily) compared to the microgram-to-low-milligram weekly injectable doses.
This also explains the strict administration requirements: the oral tablet must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before eating, drinking anything else, or taking other medications. Food, other beverages, and other drugs can dramatically reduce absorption.
The oral tablet’s roughly 1% bioavailability is exactly why clinicians managing weight reach for the injectable form instead.
What does trial data show for oral semaglutide and weight?
The PIONEER trial program evaluated oral semaglutide (14 mg daily) in adults with type 2 diabetes. While the primary endpoints were glycemic control, weight change data was also collected. PIONEER trials demonstrated meaningful weight reductions with oral semaglutide — in the range of 3–5 kg over 26 to 52 weeks in most arms — but these were typically in the context of diabetes management, not weight management as a primary goal, and at doses approved for diabetes.
Separately, Novo Nordisk has been investigating higher-dose oral semaglutide formulations for weight management — up to 50 mg daily in some trials. These are investigational formulations, not approved products. Early data suggests outcomes that begin to approach those of the injectable 2.4 mg weekly dose, but that research is ongoing and the products remain under development.
The injectable STEP trial program (Wegovy) showed average weight reductions of approximately 15% of body weight at 68 weeks with 2.4 mg weekly injections. The currently available oral formulations have not demonstrated equivalent outcomes at approved doses.
Why is compounded semaglutide usually injectable rather than oral?
When clinicians prescribe compounded semaglutide for weight management through licensed 503A pharmacies, the formulation is most commonly subcutaneous injectable, though clinician-prescribed oral compounded forms exist. Several reasons drive the injectable default:
- SNAC is proprietary: The oral absorption technology Novo Nordisk uses for Rybelsus is patent-protected. 503A compounding pharmacies cannot replicate the same SNAC-based formulation, so clinician-prescribed oral compounded semaglutide uses different formulation approaches, and its absorption profile is not characterized in large trials the way SNAC-based Rybelsus is.
- The injectable form has established outcomes data: The clinical evidence base for injectable semaglutide at 2.4 mg weekly for weight management is robust. Prescribers have a clear reference point; the oral tablet at 14 mg daily for weight management (rather than diabetes) is not a well-characterized protocol.
- Adherence and absorption reliability: Weekly injections avoid the daily fasting-window adherence requirement of oral semaglutide, and injection delivery sidesteps GI absorption variability.
What about patients who want to avoid injections?
If you have a genuine aversion to self-injection, raise it with a clinician during your intake: clinician-prescribed oral compounded semaglutide, such as a daily tablet, may be an option. An injection aversion is never a reason to seek out unregulated oral “semaglutide” products.
The self-injection required for compounded semaglutide is a small-gauge subcutaneous injection — similar in needle size and technique to an insulin pen or at-home allergy injection. Many patients who are anxious about it before starting find the process straightforward within a week or two. Your prescribing clinician or the platform you work with should provide injection training.
What you should avoid entirely: any oral supplement, patch, drop, or OTC product marketed as “semaglutide” or “natural GLP-1.” Semaglutide is a prescription-only medicine, so an over-the-counter product is a different category entirely from clinician-prescribed compounded semaglutide dispensed by a licensed 503A pharmacy, and many such products make weight loss claims their ingredient labels cannot justify. The FTC and FDA have both taken action against misleading GLP-1-adjacent products in this category.
Frequently asked questions
What is the oral semaglutide dosage for weight loss?
The FDA-approved oral semaglutide tablet (brand name Rybelsus) is approved for type 2 diabetes management, not weight loss. It is available in 3 mg, 7 mg, and 14 mg doses. There is no FDA-approved oral semaglutide specifically indicated for weight management — that indication belongs to injectable semaglutide (Wegovy, 2.4 mg subcutaneous weekly). Research is ongoing into higher-dose oral formulations for weight management, but none have received FDA approval for that purpose as of 2026.
Is oral semaglutide as effective as injectable for weight loss?
At equivalent doses, oral semaglutide has lower bioavailability than injectable due to first-pass hepatic metabolism and the absorption conditions required (specific fasting requirements). Clinical trial data shows oral semaglutide at 14 mg daily produces meaningful weight reduction, but the published weight loss outcomes are generally lower than those seen with the 2.4 mg injectable weekly regimen studied in the STEP trials. Higher-dose oral formulations are in trials and show more comparable outcomes.
Can compounding pharmacies make oral semaglutide?
Yes. Licensed 503A pharmacies prepare compounded semaglutide both as a subcutaneous injectable and as clinician-prescribed oral forms such as a daily tablet. Oral delivery of peptides presents real formulation challenges — peptides are degraded by digestive enzymes and have limited GI absorption without specific delivery systems. The branded Rybelsus tablet uses a proprietary absorption enhancer (SNAC) specific to Novo Nordisk's formulation, so compounded oral semaglutide is a different formulation approach rather than a copy of Rybelsus. Like every compounded medication, it is not FDA-approved; a clinician weighs the delivery-route tradeoffs during review.
Should I take oral or injectable semaglutide for weight management?
This is a clinical decision for your prescribing clinician, not a question with a universal answer. In practice, most clinicians managing weight prescribe injectable semaglutide (or compounded injectable semaglutide) for weight management goals because the bioavailability, published outcomes data, and dosing flexibility are superior to the currently approved oral tablet. If you have specific preferences or contraindications to injections, discuss them at intake.
What are the fasting requirements for oral semaglutide?
The FDA-approved Rybelsus must be taken on an empty stomach with no more than 4 oz of water, at least 30 minutes before any food, other beverages, or other medications. This is critical for bioavailability — food and other agents significantly reduce absorption. Missing this window meaningfully reduces the effective dose. This adherence burden is one reason clinicians prefer the injectable form for sustained weight management protocols.
